UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form SD

SPECIALIZED DISCLOSURE REPORT

Alexza Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

DELAWARE   000-51820   77-0567768

(State or Other Jurisdiction of

Incorporation)

  (Commission File Number)  

(IRS Employer Identification

Number)

 

2091 Stierlin Court

Mountain View, CA

  94043
(Address of Principal Executive Offices)   (Zip Code)

 

Mark Oki   (650)944-7000

(Name and telephone number, including area code, of the person to contact

in connection with this report.)

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

x Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2013.

Section 1—Conflict Minerals Disclosure

Alexza Pharmaceuticals, Inc. evaluated its current product lines and determined that certain product we manufacture or contract to manufacture contain tin, tungsten, tantalum and/or gold (3TG). The survey of our suppliers determined that our supply chain is Conflict Free Undeterminable and as a result we have filed a Conflict Minerals Report.

Conflict Minerals Disclosure

A copy of The Company’s Conflict Minerals Report is provided as Exhibit 1.02 hereto and is publicly available at: www.alexza.com under “Corporate Governance”.

Section 2—Exhibits

Exhibit 1.02—Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

Alexza Pharmaceuticals, Inc.

(Registrant)

 

 

/s/ Thomas B. King

By Thomas B. King

President and Chief Executive Officer

June 2, 2014